Fuel the Future of Psychedelic Journalism
Want to financially support original, independent reporting like this? You can! Donate at the link below, or just click the advertisement at the top of this article - no purchases or personal information sharing required
Inside PSA's Market Directory
Every psychedelic, cannabis and neuro‑pharma stock PSA follows now sits on one free page. The Market Directory tracks 48 listings, from Compass Pathways and GH Research to Trulieve, Eli Lilly and the AdvisorShares Psychedelics ETF (PSIL), with live prices and charts for each one.
It's open to every reader. There's no sign‑in to browse, no paywall, and no company pays to be listed.
PSA covers the decisions that move this sector, from FDA reviews to drug scheduling. The directory puts the market side of those stories next to our reporting.
What you can do there
Search and filter the full list. Find any company by ticker, name or former name, then narrow by sector: cannabis (24), biotech (7), psychedelics (7), pharma (4) and funds and ETFs (4), plus a clinic operator and an Australian psychedelic biotech.
Open a company profile. Each listing has its own page with a live chart, links to the company's website and investor relations, and the PSA stories, commentary and NewsWire items that mention it.
Compare up to four companies. Read their charts and fundamentals side by side in one row.
Test a pick against the market. Stock Analysis takes an amount and a date range and shows how up to five listings did against the S&P 500 and the Nasdaq, using daily closing prices adjusted for splits and dividends.
Check the Market Calendar. Upcoming earnings dates, Federal Reserve meetings and U.S. market holidays, all in one place.
Save a watchlist, a portfolio and price alerts. With a free reader account, star the stocks you follow, log your holdings to see their value and gain or loss, and set an alert on any listing.
Follow crypto, too. 17 major coins, from Bitcoin and Ethereum to Solana, with prices that refresh every 15 seconds.
Note: Prices may be delayed up to 15 minutes.
Earnings dates are provider estimates, not company announcements.
For information only, not investment advice.
With Psilocybin Doses Projected Up to $22,000, Usona and Compass Race Toward FDA Approval
PSA's Sunday Sound‑Off, November 8, 2026
FDA answers lawmakers on psychedelic trials
Weekly Psychedelic Policy Briefing, November 10, 2026
Know someone who follows this sector?
Forward this email, or send them to PsychedelicAmericas.Org to subscribe free.
Not what you’re looking to read? We get it!
Pick the PSA Content you want to see by updating your preferences at the link below
Until Next Time,
The Psychedelic State(s) of America Team


